Patent ID: 8759016
Filing Date: 2014-06-24
Classification: C12Q,G01N

Abstract:
1. A method of assessing risk of organ rejection, organ rejection itself or severity of organ rejection, comprising: contacting a first sample comprising T-cells and B-cells obtained from a patient in need of or having received an organ transplant from a donor with a viable donor antigen from a donor under conditions sufficient to induce T-cytotoxic memory cell proliferation by the viable donor antigen; contacting a second sample comprising T-cells and B-cells obtained from the patient in need of or having received an organ transplant with a viable third-party antigen under conditions sufficient to induce T-cytotoxic memory cell proliferation by the viable third-party antigen; measuring T-cytotoxic memory cell proliferation or an inflammatory response induced by the viable donor antigen by detecting a plurality of markers in the first sample following contacting the first sample with the viable donor antigen, wherein the plurality of markers comprises CD154, at least one T-cytotoxic cell marker and at least one T-memory cell marker, measuring T-cytotoxic memory cell proliferation or an inflammatory response induced by the viable third party antigen by detecting a plurality of markers in the second sample following contacting the second sample with the viable third-party antigen, wherein the plurality of markers comprises CD154, at least one T-cytotoxic cell marker and at least one T-memory cell marker; and determining the ratio of T-cytotoxic memory cell proliferation or an inflammatory response induced by viable donor antigen in the first sample to T-cytotoxic memory cell proliferation or an inflammatory response induced by viable third-party antigen in the second sample, wherein a ratio of greater than one indicates risk of organ rejection, organ rejection itself or increased severity of organ rejection.